Sunmax Biotechnology Co., Ltd.
4728
Rank in Stocks
#10815
Established in Tainan City, Taiwan, in 2001, Sunmax Biotechnology Co., Ltd.... Established in Tainan City, Taiwan, in 2001, Sunmax Biotechnology Co., Ltd. functions as a biomedical enterprise. The company specializes in the development, manufacturing, and commercialization of collagen-based medical devices across Taiwan and mainland China. Its diverse product line encompasses Porcogen, a sterile, purified collagen solution valuable for medical device applications, tissue engineering, and research. Sunmax also supplies various dermal fillers, including the Sunmax collagen implant series (I-Plus, I) and FACIALGAIN collagen implants (with and without lidocaine), engineered for correcting facial aesthetic concerns such as wrinkles. For dental procedures, they provide specialized collagen-based solutions like Sunmax collagen dental bone grafts, membranes, and granules, used for augmenting or reconstructing the alveolar ridge, extraction sockets, and in periodontics. Additionally, the Sunmax collagen bone graft matrix serves as a bone void filler that naturally resorbs and facilitates new bone formation during recovery. The company's offerings extend to skincare products, such as Sunmax 12 jiao didi spray, Sunmax 11 collagen moisturizing cream, and a general collagen skincare line, all designed for post-dermal filler treatment aftercare.
Share Price
$11.83
Last synced: 2026-11-10
Market Cap
$644.19M
Change (1 day)
-1.02%
Change (1 year)
-7.78%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Sunmax Biotechnology Co., Ltd. (4728)
Category
Healthcare
EPS for Sunmax Biotechnology Co., Ltd. (4728)
EPS as of June 2026 TTM: $0.46
According to Sunmax Biotechnology Co., Ltd.'s latest financial reports, its current EPS (TTM) is $0.46. At the end of 2025 the company had an EPS of $0.42, an increase over its 2024 EPS of $0.38.
EPS history for Sunmax Biotechnology Co., Ltd. from 2019 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $0.46 | 9.52% |
| 2025 | $0.42 | 11.79% |
| 2024 | $0.38 | 1.44% |
| 2023 | $0.37 | 17.18% |
| 2022 | $0.32 | 96.44% |
| 2021 | $0.16 | 4.56% |
| 2020 | $0.16 | 153.01% |
| 2019 | $0.06 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | 3,304.35% |
US
|
|
| $-7.07 | -1,636.96% |
US
|
|
| $-5.29 | -1,250.00% |
AU
|
|
| $12.88 | 2,700.02% |
BE
|
|
| $21.56 | 4,586.96% |
NL
|
Questions about Sunmax Biotechnology Co., Ltd.'s earnings per share (EPS)
What is Sunmax Biotechnology Co., Ltd.'s earnings per share (EPS)?
Sunmax Biotechnology Co., Ltd.'s earnings per share (EPS) over the last twelve months is $0.46, as of Jun 2026.
What was Sunmax Biotechnology Co., Ltd.'s earnings per share (EPS) in 2025?
In 2025, Sunmax Biotechnology Co., Ltd.'s earnings per share (EPS) was $0.42, 10.53% more than in 2024 ($0.38).
How has Sunmax Biotechnology Co., Ltd.'s earnings per share (EPS) changed since 2020?
From 2020 to 2025, Sunmax Biotechnology Co., Ltd.'s earnings per share (EPS) went from $0.16 to $0.42, an average growth of 21.29% a year.
How does Sunmax Biotechnology Co., Ltd.'s earnings per share (EPS) compare with similar companies?
Sunmax Biotechnology Co., Ltd.'s earnings per share (EPS) ($0.46) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.